|drug2580||No intervention / Evaluation of the ferritin and glycosylated ferritin by standard approved serological tests Wiki||0.50|
|drug2494||Nafamostat Mesilate Wiki||0.29|
|D018352||Coronavirus Infections NIH||0.05|
There are 4 clinical trials
The prone position consists of placing the patient on his or her stomach with the head on the side, during sessions lasting several hours a day and could help spontaneous ventilate the patient.
Description: PaO2 improvement of more than 20% after one hour in prone position in spontaneously breathing non intubated COVID-19 patients.Measure: Proportion of "responder" patients to prone position Time: 1 hour
Description: PaO2 improvement of more than 20% at 6 to 12 hours from return to supine position.Measure: proportion of "persistent responders" patients after prone position Time: 1 day
Description: PaO2 at 1 hour from the start of prone position and at 6 to 12 hours afterreturn to supine position.Measure: Evolution of PaO2 Time: 1 day
Description: Look for an association between the time spent in Prone positione and persistent responder or not;Measure: Duration of prone positioning and PaO2 evolution Time: 2 days
Description: proportion of patients improving their arterial saturation within 1 hour of Prone PositionMeasure: Evolution of Spo2 Time: 1 hour
Description: evolution of the EVA scores for dyspnea at 1 hour from the start of the Prone Position and at 6 hours after the end of the Prone PositionMeasure: EVA Dyspnea Time: 1 day
Description: proportion of patients intolerant to prone position (Prone Position <1h);Measure: Intolerance to prone positioning Time: 1 day
Description: proportion of patients who can maintain prone position for more than 3 h.Measure: Tolerance to prone positioning Time: 1 day
The consensus therapeutic strategy implies that COVID patients with acute lung injury due to coronavirus are routinely placed in prone position in an attempt to improve oxygenation by increasing ventilation homogeneity. The purpose of the study is to quantify with the electrical impedance tomography (EIT) the changes in the ventilation and aeration in the dorsal regions of the lung when the patient is placed in prone position.
Description: Change in the ratio of tidal electrical impedance variation in the dorsal and total lung areasMeasure: Tidal electrical Impedance Time: One hour before turning to prone or supine positioning
Description: Changes in intrapulmonary shunt fractionMeasure: Intrapulmonary shunt Time: One hour before turning to prone or supine positioning
Description: Changes in the phase three slope of the volumetric capnogramMeasure: Volumetric capnography Time: One hour before turning to prone or supine positioning
COVID-PRONE is a multicenter, pragmatic, single-blind, 2-arm, parallel, randomized controlled trial seeking to compare the pre-emptive prone positioning (i.e. encouraging patients to adopt a prone position before they require mechanical ventilation) to the control arm of standard care alone. Randomization will be stratified by site.
Description: I) The ratio between the patient's oxygen saturation and the amount of oxygen they're inspiring, II) Sustained (i.e., more than 5 minutes) drop in oxygen saturation less than 88% in the prone position on the same oxygen therapy required to maintain a saturation of >92% in the supine position.Measure: Feasibility outcome: Change in oxygen saturation before and after prone positioning (to be measured for 72 hours beginning at the time of randomization), which will be calculated as: Time: 72 hours
Description: Rate of serious adverse events as identified through routine care by the patient's attending physician (e.g., venous thromboembolism, pneumonia) or through objective testing (i.e., death, transfer to the intensive care unit). Notably, bacterial pneumonia will be pragmatically defined through the combination of a chest x-ray report identifying evidence of pneumonia and the receipt of antibiotics known to treat pneumoniaMeasure: Feasibility outcome: Rate or serious adverse events Time: Up to 7 days
Description: The patients will be called on day 3 and 7. The research assistant/coordinator will ask the patient to estimate the number of hours spent in prone position.Measure: Feasibility outcome: Adherence to prone positioning Time: Day 3 and day 7
Prone positioning is known to improve the PaO2/FiO2 ratio and reduce mortality in patients with ARDS managed in the critical care setting. Therefore, it is incorporated into regular clinical practice of managing patients with ARDS in critical care and is being used as such in the COVID-19 outbreak. Given that prone positioning is recommended by the Intensive Care Society in non-ventilated patients with COVID-19, there is an urgent need to better understand the physiological effects of prone positioning in such cases. Furthermore, the translation and applicability of such a low-cost non-invasive intervention in a wider group of patients with pneumonia not specific to covid-19 infection, is an important consideration that merits investigation. This single-centred observational study conducted at Cambridge University Hospitals NHS Foundation Trust aims to improve understanding of physiological effects of prone positioning in non-ventilated patients with COVID-19 and a control group of patients with non-COVID-19 related pneumonia. The study also aims to incorporate a small subset of patients, with an approximately even spread of COVID-19 and non-COVID cases, which allows for an additional exploratory descriptive report on prone positioning over a 24-hour period. This study proposes that prone positioning improves oxygenation in non-ventilated patients with pneumonia (COVID-19 related or not) requiring supplemental oxygen managed outside of the critical care setting.
Description: Oxygenation measured by peripheral saturations in relation to inspired oxygen (FiO2) when patient is prone versus a supine or lateral position using a Masimo deviceMeasure: Peripheral Oxygen saturation Time: 1 year (June 2021)
Description: To evaluate effects of prone position versus supine or lateral position on derived measures of oxygenation (Pa02:Fi02 ratio calculated from formulae) in relation to inspired oxygen.Measure: PaO2 :FiO2 ratio calculated from formulae Time: 1 year (June 2021)
Description: Effects of prone versus supine or lateral position on respiratory rateMeasure: Respiratory rate measured with Masimo device Time: 1 year (June 2021)
Description: Effects of prone versus supine or lateral position on heart rateMeasure: Heart rate measured with Masimo device Time: 1 year (June 2021)
Description: Effects of prone versus supine or lateral position on blood pressureMeasure: Blood pressure measured with Masimo device Time: 1 year (June 2021)
Description: To evaluate whether prone position reduces patient reported severity of breathlessness assessed by visual assessment score.Measure: Patient reported severity of breathlessness on a continuous linear scale of 0 to 10cm (10cm being the most severe) Time: 1 year (June 2021)
Description: To evaluate patient tolerability of prone position assessed by visual assessment score.Measure: Patient tolerability of prone position on a continuous linear scale of 0 to 10cm (10cm being the most unacceptable) Time: 1 year (June 2021)
Description: To evaluate investigator experience of delivering prone positioning in this study by free text question responses.Measure: Investigator experience of delivering prone positioning Time: 1 year (June 2021)
Description: To evaluate the natural position of patients (with the aid of position sensors) who are encouraged to position themselves prone over a 24-hour period (which include sleep) and relationship with oxygenationMeasure: To assess patient's peripheral oxygen saturation Time: 1 year (June 2021)
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports